Consort Medical plc Receives Average Rating of “Buy” from Analysts (LON:CSRT)
Consort Medical plc (LON:CSRT) has been given an average rating of “Buy” by the eleven analysts that are currently covering the stock, ARN reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is GBX 942.50 ($16.00).
Shares of Consort Medical plc (LON:CSRT) opened at 900.70 on Wednesday. Consort Medical plc has a one year low of GBX 803.00 and a one year high of GBX 1113.00. The stock has a 50-day moving average of GBX 939.0 and a 200-day moving average of GBX 944.4. The company’s market cap is £259.4 million.
A number of analysts have recently weighed in on CSRT shares. Analysts at Shore Capital upgraded shares of Consort Medical plc to a “buy” rating in a research note on Wednesday, July 2nd. Separately, analysts at Westhouse Securities reiterated a “buy” rating on shares of Consort Medical plc in a research note on Friday, June 20th. They now have a GBX 1,100 ($18.68) price target on the stock. Finally, analysts at Investec raised their price target on shares of Consort Medical plc from GBX 1,005 ($17.07) to GBX 1,021 ($17.34) in a research note on Tuesday, June 17th. They now have a “buy” rating on the stock.
Consort Medical plc is a healthcare company focused on medical technologies. The principal activities of the Company are the design, development and manufacture of specialty medical drug delivery devices and services to the pharmaceutical industry through its Bespak Division and disposable airway management products for critical care settings in hospitals and pre-hospital settings through its King Systems Division.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.